{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:00:40Z","timestamp":1792839640243,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Intercept Pharmaceuticals, Inc"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jhep.2020.02.033","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T20:46:04Z","timestamp":1583786764000},"page":"94-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":185,"title":["A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis"],"prefix":"10.1016","volume":"73","author":[{"given":"Kris V.","family":"Kowdley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Vuppalanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarosa","family":"Floreani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Andreone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas F.","family":"LaRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rushbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon M.","family":"Hirschfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pencek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"MacConell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher L.","family":"Bowlus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jhep.2020.02.033_bib1","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis - a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.jhep.2020.02.033_bib2","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMra1506330","article-title":"Primary sclerosing cholangitis","volume":"375","author":"Lazaridis","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.jhep.2020.02.033_bib3","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG clinical guideline: primary sclerosing cholangitis","volume":"110","author":"Lindor","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jhep.2020.02.033_bib4","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/hep.30479","article-title":"Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system","volume":"69","author":"Goode","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhep.2020.02.033_bib5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhep.2012.10.013","article-title":"Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis","volume":"58","author":"Al Mamari","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"7","key":"10.1016\/j.jhep.2020.02.033_bib6","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cgh.2012.12.032","article-title":"Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis","volume":"11","author":"Lindstrom","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11\u201312","key":"10.1016\/j.jhep.2020.02.033_bib7","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/apt.12979","article-title":"Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis","volume":"40","author":"Rupp","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jhep.2020.02.033_bib8","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2020.02.033_bib9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"Ursodiol for primary sclerosing cholangitis. Mayo primary sclerosing cholangitis-ursodeoxycholic acid study group","volume":"336","author":"Lindor","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.jhep.2020.02.033_bib10","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study","volume":"129","author":"Olsson","year":"2005","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhep.2020.02.033_bib11","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhep.2020.02.033_bib12","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1194\/jlr.M081935","article-title":"FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver","volume":"59","author":"Papazyan","year":"2018","journal-title":"J\u00a0Lipid Res"},{"issue":"5","key":"10.1016\/j.jhep.2020.02.033_bib13","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A\u00a0randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2020.02.033_bib14","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2020.02.033_bib15","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver Injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2020.02.033_bib16","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.jhep.2020.02.033_bib17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jhep.2020.02.033_bib18","doi-asserted-by":"crossref","first-page":"e000256","DOI":"10.1136\/bmjgast-2018-000256","article-title":"Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel","volume":"6","author":"Pate","year":"2019","journal-title":"BMJ Open Gastroenterol"},{"issue":"3","key":"10.1016\/j.jhep.2020.02.033_bib19","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.29882","article-title":"Design and endpoints for clinical trials in primary sclerosing cholangitis","volume":"68","author":"Ponsioen","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2020.02.033_bib20","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.28256","article-title":"Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process","volume":"63","author":"Ponsioen","year":"2016","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820301604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820301604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T15:15:56Z","timestamp":1716650156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827820301604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0168827820301604"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2020.02.033","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.02.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}